Study shows encouraging therapeutic options for patients with relapsed multiple myeloma

Mount Sinai researchers have published results that show encouraging therapeutic options for patients with the blood cancer multiple myeloma after first-line treatment with bispecific antibodies fails.

Related Keywords

Samir Parekh ,Emily Henderson ,Translational Research In Myeloma ,Icahn School Of Medicine At Mount Sinai ,Tisch Cancer Institute ,Icahn Genomics Institute ,Blood Advances ,Mount Sinai ,Senior Author ,Translational Research ,Cancer Clinical Investigation ,Icahn School ,Myeloma ,Antibodies ,Ntibody ,Ntigen ,Flood ,Blood Cancer ,Dancer ,Cancer Treatment ,Fell ,Children ,Chimeric Antigen Receptor ,Clinical Trial ,Geriatrics ,Health Care ,Hospital ,Immune System ,Medicine ,Multiple Myeloma ,Eceptor ,Research ,Surgery ,T Cell ,Humor ,